Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiogenedWAR:BGD 69 Days Payable is 140.48 as of Mar. 2026, which is 7% above its 10-year median of 130.68. GuruFocus rates WAR:BGD with a GF Score™ of 69/100 and a GF Value™ of zł23.90 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Biogened ranks better than 69.36% on this metric.
Biogened's average Accounts Payable for the
three
months ended in Mar. 2026 was zł14.3 Mil. Biogened's Cost of Goods Sold for the
three
months ended in Mar. 2026 was zł9.3 Mil.
Hence, Biogened's Days Payable for the
three
months ended in Mar. 2026 was 140.48.
The historical rank and industry rank for Biogened's Days Payable or its related term are showing as below:
WAR:BGD'
s Days Payable Range Over the Past 10 Years
Min: 95 Med: 130.68 Max: 161.13
Current: 130.78
During the past 13 years, Biogened's highest Days Payable was 161.13. The lowest was 95.00. And the median was 130.68.
WAR:BGD's Days Payable is ranked better than 69.36% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs WAR:BGD: 130.78
Biogened's Days Payable
increased
from Mar. 2025 (115.34) to Mar. 2026 (140.48).
It may suggest that Biogeneddelayed paying its suppliers.
Biogened Days Payable Related Terms
Biogened Days Payable Historical Data
* Premium members only.
The historical data trend for Biogened's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:BGD vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biogened's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogened Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogened's Days Payable distribution charts can be found below:
* The bar in red indicates where Biogened's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Biogened's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogened (WAR:BGD) has a Days Payable of 140.48 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biogened and its competitors. This is near median its historical median of 130.68. Over the past decade, Biogened's Days Payable has ranged from 95.00 to 161.13. According to the industry distribution chart, Biogened ranks #284 out of 927 companies in the Drug Manufacturers industry, placing it in the top 30.6%.
Is Biogened's Days Payable too high?
Biogened's current Days Payable of 140.48 is near median its 10-year median of 130.68. Over the past 10 years, this metric has ranged from a low of 95.00 to a high of 161.13. The Drug Manufacturers industry median Days Payable is 90.38. Biogened's value of 140.48 is 55.4% above this industry median. Based on the distribution chart, Biogened ranks #284 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biogened has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biogened ranks #284 out of 927 companies for Days Payable. This puts Biogened in the upper half of its industry. The industry median Days Payable is 90.38. Biogened's value of 140.48 is 55.4% above this benchmark. Historically, Biogened's own Days Payable has ranged from 95.00 to 161.13 over the past decade. While the company's 10-year median is 130.68 vs. the industry median of 90.38, Biogened has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogened's current Days Payable of 140.48 is 55.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biogened and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogened's current Days Payable is 140.48, which is near median its own 10-year median of 130.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.90, compared to a current price of zł18.50 — trading 22.6% below its estimated fair value. The current Days Payable is 140.48, which is near median its 10-year median of 130.68 and 55.4% above the Drug Manufacturers industry median of 90.38. Biogened's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biogened (WAR:BGD), the current Days Payable is 140.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogened (WAR:BGD) Overvalued in 2026?
Based on GuruFocus' analysis, Biogened stock appears to be undervalued.
The current stock price of zł18.50 is trading 22.6% below its estimated GF Value™ of zł23.90.
GuruFocus considers Biogened to be Modestly Undervalued.
Key valuation signals for WAR:BGD:
Days Payable: 140.48 (near median its 10-year median of 130.68)
GF Value™: zł23.90 vs. price of zł18.50 (22.6% below fair value)
Industry Position: 55.4% above the Drug Manufacturers median (#284 of 927)
No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
69GF Score
Get the complete analysis for WAR:BGD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:BGD has been successfully added to your 
